Prevention of covid-19 and other acute respiratory infections with cod liver oil supplementation, a low dose vitamin D supplement: quadruple blinded, randomised placebo controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement), published as a randomized controlled trial.

Who Took Part

According to the abstract, 34 adults were involved.

By PubMed's age tags, the people studied were adults.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

Quadruple blinded, randomised placebo controlled trial.

Norway, 10 November 2020 to 2 June 2021.

What Was Measured

The subject headings attached to it are COVID-19, Cod Liver Oil, Dietary Supplements, SARS-CoV-2 and Vitamin D.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement) in 34 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (BMJ (Clinical research ed.)), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, all human trials.